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Vesicle-membrane-protein-associated protein A
(VAPA) and oxysterol-binding protein (OSBP) regu-
late intracellular cholesterol homeostasis, which is
required for many virus infections. During entry,
viruses or virus-containing vesicles can fuse with
endosomal membranes to mediate the cytosolic
release of virions, and alterations in endosomal
cholesterol can inhibit this invasion step. We show
that the antiviral effector protein interferon-inducible
transmembrane protein 3 (IFITM3) interacts with
VAPA and prevents its association with OSBP,
thereby disrupting intracellular cholesterol homeo-
stasis and inhibiting viral entry. By altering VAPA-
OSBP function, IFITM3 induces a marked accumula-
tion of cholesterol in multivesicular bodies and late
endosomes, which inhibits the fusion of intraluminal
virion-containing vesicles with endosomal mem-
branes and thereby blocks virus release into the
cytosol. Consequently, ectopic expression or deple-
tion of the VAPA gene profoundly affects IFITM3-
mediated inhibition of viral entry. Thus, IFITM3
disrupts intracellular cholesterol homeostasis to
block viral entry, further underscoring the impor-
tance of cholesterol in virus infection.
INTRODUCTION
Cellular lipid membranes form barriers that tightly regulate the
entry and egress of many viruses. Cholesterol is essential in lipid
raft membranes, organized sections within plasma membranes,
endosomal compartments, and other organelles. Numerous
studies have demonstrated that not only do lipid raft membranes
and cholesterol play vital roles in cellular pathways and cell bio-
logical phenomena, but they also have critical functions in viral
infection (Man˜es et al., 2003; Schroeder, 2010). Specifically,
membrane lipid rafts are involved in entry, assembly, and452 Cell Host & Microbe 13, 452–464, April 17, 2013 ª2013 Elsevierbudding of many nonenveloped and enveloped viruses, such
as influenza A virus (IAV), vesicular stomatitis virus (VSV), human
immunodeficiency virus-1 (HIV-1), Epstein-Barr virus (EBV),
Ebola virus, Marburg virus, and herpes simplex virus (HSV)
(Chang et al., 2012; Gianni and Campadelli-Fiume, 2012; Veit
and Thaa, 2011; Wang et al., 2009). Intracellular cholesterol
levels increase by endocytosis of extracellular cholesterol as
well as de novo biosynthesis (Ikonen, 2008; Ioannou, 2001).
The modulation of intracellular cholesterol homeostasis within
cells, especially in the endosomal compartment, has dramatic
effects on the entry stage of viral infection (Carette et al., 2011;
Danthi and Chow, 2004; Gruenberg, 2009; Kobayashi et al.,
1999; Poh et al., 2012). Changes in intracellular cholesterol
homeostasis during the course of an infection are therefore
either part of a cellular reprogramming process facilitating viral
replication and/or a specific infection-induced host defense
response. Thus, intracellular cholesterol homeostasis may be a
potential target for disrupting ‘‘virus-containing cargos’’ and
reveal avenues to combat viral infections.
Under normal physiological conditions, cholesterol is deliv-
ered to endosomal compartments, subjected to hydrolysis,
and then transported to the cytosol. In addition, de novo synthe-
sized cholesterol, another source of cholesterol in the cell, must
be transported from the endoplasmic reticulum (ER) to other
organelles, such as endosomes, lysosomes, Golgi, mitochon-
dria, and plasma membranes (Holthuis and Levine, 2005).
Vesicle-associated membrane protein (VAMP)-associated pro-
tein A (VAPA) and oxysterol-binding protein (OSBP) are two
important proteins implicated in these processes (Raychaudhuri
and Prinz, 2010). Specifically, the major sperm protein (MSP)
domain of VAPA interacts with the FFAT motif of OSBP to trans-
fer cholesterol from the ER to organelles; however, detailed
mechanisms of VAPA-OSBP complex-mediated cholesterol
transport are still elusive (Holthuis and Levine, 2005; Levine,
2004). On the other hand, as seen in Niemann-Pick type C1
(NPC1) disease, disturbance in cholesterol transport from endo-
somal compartment to cytosol results in cholesterol accumula-
tion in late endosomes and multivesicular bodies (MVBs)
(Maxfield and Tabas, 2005; Subramanian and Balch, 2008).
Because many viruses, including IAV and VSV, enter the cyto-
plasm by crossing the endosomal compartment with MVBsInc.
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somes and MVBs impairs viral function, preventing delivery of
the viral capsid or genome to the cytosol (Chevallier et al.,
2008; Sobo et al., 2007). For example, during VSV infection,
fusion of the viral envelope with endosomal membranes and
nucleocapsid release occur sequentially at two successive steps
of the endocytic pathway; initial fusion occurs in transport inter-
mediates between early and late endosomes, followed by the
back-fusion of internal vesicles with the limiting membrane of
late endosomes. The second step depends on the late endoso-
mal phospholipid, lipid lysobisphosphatidic acid (LBPA), and is
regulated by phosphatidylinositol-3-phosphate (PtdIns3P)
signaling via the PtdIns3P-binding protein Snx16 (Kobayashi
et al., 1999; Le Blanc et al., 2005). On the other hand, HIV-1 relies
on cholesterol-laden lipid raft membrane microdomains for entry
into and egress out of susceptible cells. Specifically, intact intra-
cellular cholesterol trafficking pathways mediated by choles-
terol-shuttling NPC1 are needed for efficient HIV-1 release and
production (Tang et al., 2009). Furthermore, recent studies
have also identified that membrane fusion mediated by filovirus
glycoproteins and viral escape from the vesicular compartment
require the NPC1 protein (Carette et al., 2011; Coˆte´ et al.,
2011). Thus, integrity of membrane lipid rafts and cholesterol
homeostasis are essential for the ordered assembly and release
of a number of different infectious virus particles.
Host innate immunity is activated upon viral entry, thus acting
as the first line of defense against viral infection, mainly via
antiviral interferon (IFN)-stimulated genes (ISGs) (Sadler andWil-
liams, 2008). Approximately, 300 ISGgenes have been identified,
but the exact molecular mechanisms of many remain elusive
(Schoggins et al., 2011; Yan and Chen, 2012). We have recently
shown that IFN-inducible transmembrane (IFITM) proteins
restrict the replication of multiple viruses, including IAV, SARS
coronavirus, filoviruses (Ebola and Marburg viruses), flaviviruses
(dengue and West Nile viruses), and VSV (Bailey et al., 2012;
Brass et al., 2009). Others have also demonstrated that IFITM
proteins restrict HIV-1 (Lu et al., 2011). In contrast, IFITMs do
not inhibit the entry processes of amphotropic mouse leukemia
virus (MLV), Machupo virus (MACH), Lassa virus (LASA), or lym-
phocytic choriomeningitis virus (LCMV) (Diamond and Farzan,
2013). The IFITM isoforms are relatively small (130 amino acids)
and share a common topology of two conserved transmembrane
domains, a short highly conserved cytoplasmic region, and
luminal amino- and carboxyl termini (Siegrist et al., 2011; Wee
et al., 2012). Recent studies showed that S-palmitoylation and
ubiquitination of IFITM3 play crucial roles in its function (Yount
et al., 2010, 2012) and that IFITM3may influence v-ATPase com-
plex activity and facilitates the subcellular localization of clathrin
(Wee et al., 2012). Three additional studies showed that the
N-terminal 21 amino acid residues of IFITM3 are required for its
antiviral activity against VSV and IAV (Everitt et al., 2012; Jia
et al., 2012;Weidner et al., 2010). Finally, IFITM-mediated restric-
tion can bebypassed by inducing viral fusion at the plasmamem-
brane, suggesting that the site or mechanism of viral entry can
affect sensitivity to IFITM-mediated restriction (Huang et al.,
2011). Despite current active investigation, a detailed mecha-
nism of IFITM-mediated antiviral activity is still elusive.
In this study, we describe a mechanism by which IFITM pro-
teins exert their antiviral activity. We found that IFITM1, IFITM2,Cell Hand IFITM3 interact with VAPA, and this interaction antago-
nizes VAPA-OSBP function, disturbing intracellular cholesterol
homeostasis, resulting in cholesterol-laden late endosomal
compartments that block viral release to the cytosol. In contrast,
VAPA expression facilitated the fusion of internal vesicles
with the limiting membrane of endosomes, allowing viral release
to the cytosol. IFITM inhibition of VAPA-OSBP functions to
disturb the integrity of cholesterol homeostasis, and therefore
blocking viral entry represents an antiviral strategy that offers it-
self as a target for therapeutic avenues to combat viral infections.
RESULTS
IFITM and VAPA Interaction
To identify how IFITM3 mediates antiviral activity, a yeast two-
hybrid (Y2H) screening assay was performed. Full-length IFITM3
was cloned into the pGBKT7 vector as bait, and AH109 yeast
expressing IFITM3 was transformed with a human leukocyte
matchmaker complementary DNA (cDNA) library. This Y2H
screening revealed that IFITM3 interacts with full-length VAPA.
An immunoprecipitation (IP) assay confirmed the interaction of
IFITM1, IFITM2, and IFITM3with endogenous VAPA in A549 cells
(Figure 1A). Interaction of IFITM3 with VAPA was further
confirmed under overexpression conditions (Figures 1B and
1C). To identify which domain(s) of VAPA are responsible for
IFITM interaction, VAPA and IFITM were fragmented and cloned
into the GAL4 activation and DNA binding vectors, respectively.
Y2Hmapping study revealed that the IFITM108-128 fragment con-
taining the transmembrane 2 (TM2) domain alone and the
VAPA169-248 fragment containing the coiled-coil domain (CCD)
and transmembrane (TM) domain are responsible for their
interaction (Figures 1D and 1E; Figure S1A available online). A
pull-down assay with mammalian glutathione S-transferase
(GST)-IFITM fusions further confirmed that the TM2 region of
IFITM3 is sufficient for VAPA binding (Figures S1B and S1C).
IFITM1 and IFITM3 showed similar binding affinity to VAPA,
and both appeared to have a slightly higher binding affinity to
VAPA than to VAPB (Figures S1D and S1E). These results
demonstrate a specific interaction between IFITM and VAPA.
The interaction between VAPA and OSBP plays an important
role in transferring cholesterol between ER and organelles for
cholesterol homeostasis (Holthuis and Levine, 2005; Levine,
2004; Maxfield and Tabas, 2005). To test whether IFITM3 or
OSBP affects the interaction between VAPA and OSBP or
between VAPA and IFITM3, respectively, bacterially purified
GST-VAPA fusion protein (Figure S1F) was mixed with whole-
cell lysates containing OSBP and IFITM3, followed by GST
pull-down (GST-PD) and immunoblotting assay. These experi-
ments revealed that increasing VAPA-IFITM3 interaction led to
decreasing VAPA-OSBP interaction, whereas increments of
the OSBP did not affect VAPA-IFITM3 interaction (Figure 1F).
These data indicate that IFITM3 blocks the interaction between
VAPA and OSBP in a VAPA-binding dependent manner.
IFITM3-Mediated Restriction of Viral Infection
Is Dependent on VAPA Expression
It was previously shown that the IFITM3 inhibits the early stage
of viral entry (Brass et al., 2009; Feeley et al., 2011). To assess
the effects of IFITM3-VAPA interaction on viral infection, humanost & Microbe 13, 452–464, April 17, 2013 ª2013 Elsevier Inc. 453
Figure 1. IFITMs Specifically Interact with VAPA, and IFITM3 Interaction Suppresses the Interaction between VAPA and OSBP
(A) Lysates of A549-IFITM1, A549-IFITM2, or A549-IFITM3 cells were used for immunoprecipitation (IP) with anti-VAPA antibody, followed by immunoblotting (IB)
with anti-Myc antibody.
(B) Lysates of A549-Vector and A549-IFITM3 cells were used for IP and IB with the indicated antibodies. Whole-cell lysates (WCLs) were used for IB with the
indicated antibodies.
(C) Lysates of A549-Vector-VAPA-FLAG and A549-IFITM3-VAPA-FLAG cells were used for IP and IB with the indicated antibodies.
(D) Various fragments of the IFITM3 gene and three fragments of VAPA gene were used for Y2H assay.
(E) Various fragments of the VAPA gene and a full-length IFITM3 gene were used for Y2H assay.
(F) Bacterially purified GST-VAPA protein was mixed with OSBP-containing cell lysates with increasing amounts of IFITM3-containing cell lysates (left panel), or
bacterially purified GST-VAPA protein was mixed with IFITM3-containing cell lysates with increasing amounts of OSBP-containing cell lysates (right panel).
Mixtures were incubated for 2 hr at 4C, followed by GST pull-down (PD) and IB with the indicated antibodies. WCLs were used for IB with the indicated anti-
bodies. See also Figure S1.
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IFITM3-VAPA (Figure S1G) were infected with VSV or IAV PR8
strain, and viral replication was then measured using a standard
plaque assay. Not surprisingly, replication of both VSV and IAV
was dramatically restricted in A549-IFITM3 cells but slightly
elevated in A549-VAPA cells compared to A549-vector cells
(Figures 2A, 2B, and 2C). VAPA expression in A549-IFITM3 cells
effectively counteracted the IFITM3-mediated restriction of VSV
and IAV replication (Figures 2A, 2B, 2C, and S1H). To further
confirm the effect of VAPA expression on IFITM3 activity, endog-
enous VAPA expression in A549-vector and A549-IFITM3 cells
was depleted by VAPA-specific short hairpin RNA (shRNA) (Fig-
ure S1I). Viral replication showed that although depletion of the454 Cell Host & Microbe 13, 452–464, April 17, 2013 ª2013 ElsevierVAPA gene expression apparently reduced VSV and IAV replica-
tion in A549-vector cells, this effect was more apparent in A549-
IFITM3 cells (Figures 2D and 2E).
A single cycle of viral entry was also evaluated using defec-
tive pseudoretroviruses carrying various viral envelopes. As
previously shown (Brass et al., 2009), IFITM3 effectively inhibited
the entry of VSV, IAV PR8 (H1N1), and IAV Udorn (H3N1), but not
lymphocytic choriomeningitis virus (LCMV), Moloney leukemia vi-
rus (MLV),Machupovirus (MACH),andLassavirus (LASA) (Figures
2F and 2G). VAPA expression counteracted IFITM3-mediated
antiviral activity, resulting in detectable increases of VSV and IAV
entry, whereas VAPA depletion considerably suppressed VSV
and IAV entry inmock-transfected aswell as in IFITM3-expressingInc.
Figure 2. VAPA Antagonizes IFITM3-Mediated Inhibition of Viral Entry
(A) A549 cells were infected with various multiplicity of infection (m.o.i) of GFP-VSV, and replication levels were monitored by immunofluorescence microscopy
(magnification: 43).
(B) A549 cells were infected with VSV (m.o.i = 0.1), and VSV replications were determined by a standard plague assay. Values represent mean ± SD, n = 3
independent experiments.
(C) A549 cells were infected with the IAV PR8/H1N1 strain (m.o.i = 0.1), and IAV replications were determined by a standard plague assay. Values represent
mean ± SD, n = 3 independent experiments.
(D) A549-Vector and A549-IFITM3 cells were infected with lentivirus carrying either VAPA-shRNA (VAPA-sh) or SC-shRNA (SC-sh). After 2 days, A549 cells were
infected with the VSV PR8/H1N1 strain (m.o.i = 0.1), and VSV replications were determined by a standard plague assay. Values represent mean ± SD, n = 3
independent experiments.
(E) A549-Vector and A549-IFITM3 cells were infected with lentivirus carrying either VAPA-shRNA (VAPA-sh) or SC-shRNA (SC-sh). After 2 days, A549 cells were
infected with the IAV PR8/H1N1 strain (m.o.i = 0.1), and IAV replications were determined by a standard plague assay. Values represent mean ± SD, n = 3
independent experiments.
(F and G) A549 cells were incubated with MLV-EGFP virus pseudotyped with the indicated envelope protein (VSV, IAV H1N1 [PR8], IAV H3N1 [Udorn], LCMV,
MLV, MACH, or LASA). Viral entry is expressed as mean EGFP fluorescence relative to vector control cells, as measured by flow cytometry. Values represent
mean ± SD, nR 3 independent experiments.
(H) A549-Vector and A549-IFITM3 cell lines were infected with lentivirus carrying either VAPA-shRNA (VAPA-sh) or SC-shRNA (SC-sh). After 2 days, cells were
incubated with defectiveMLV-EGFP pseudotyped with the envelope protein of VSV, IAVH1N1 (PR8), or IAV H3N1 (Udorn). Viral entry is expressed asmean EGFP
fluorescence relative to vector control cells, as measured by flow cytometry. Values represent mean ± SD, nR 3 independent experiments. See also Figure S2.
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IFITM3 Disrupts Cholesterol Homeostasiscells (Figures 2F, 2G, and 2H). However, neither expression nor
depletion of the OSBP gene showed any detectable effects on
VSV entry and replication (Figures S2A, S2B, and S2C; data not
shown). These results collectively demonstrate that IFITM3-medi-
ated restrictionof viral infection isdependentonVAPAexpression,
suggesting that the VAPA gene plays an important role in viral
entry by antagonizing IFITM3 activity.Cell HIFITM3 Expression Causes Cholesterol-Laden
Endosomal Compartments
IFITM3 can be detected at the plasma membrane (Figure S2D)
but is localized primarily in endosomal and lysosomal compart-
ments as indicated by colocalization endosomal and lysosomal
markers LAMP1 and CD63 (Figure S2E). Furthermore, IFITM3
mostly colocalized with Rab7, though weakly with Rab5,ost & Microbe 13, 452–464, April 17, 2013 ª2013 Elsevier Inc. 455
Figure 3. IFITM3 Induces Cholesterol-Laden Endosomal Compartments
(A and B) A549-Vector or A549-IFITM3 cells were stained with filipin (A) or Nile Red (B), together with anti-Myc (IFITM3) or anti-CD63 antibody. Scale bars, 10 and
20 mm. The inserts at the right panels show the magnified images. The metric values (mean ± SD) in the inserts represent colocalization quantification of either
filipin with IFITM3 (0.52 ± 0.11) or Nile Red with IFITM3 (0.42 ± 0.09) calculated by Pearson’s correlation coefficient based onR20 cells.
(C) A549-IFITM3 cells were stained with filipin, together with anti-Myc (IFITM3) and anti-LBPA antibody. Scale bar, 5 mm. Colocalization between LBPA and
IFITM3 was quantified as 0.38 ± 0.10 (Pearson’s coefficient, mean ± SD, nR 20).
(D) A549-Vector, A549-IFITM3, A549-VAPA, and A549-IFITM3-VAPA cells were stained with Nile Red dye to measure their intracellular cholesterol levels by flow
cytometry. The mean fluorescence intensities (MFI) were compared and presented as relative folds compared with those of A549-Vector cells. As a positive
control, A549-Vector cells were treated with 2 mg/ml U18666A (U18), a cholesterol transport inhibitor, to induce cholesterol accumulation in endosomal com-
partments. Values represent mean ± SD, n > 3 independent experiments. Significant differences (p value < 0.05), compared to IFITM3, are marked by an asterisk.
(E) A549-IFITM3 cells were washed 3–5 times with PBS and then treatedwith different concentrations (mM) ofMbCD in free-serummedia at 37C for 45min. Cells
were then washed three times and incubatedwith defectiveMLV-EGFP pseudotypedwith VSVgp. Viral entry is expressed asmean EGFP fluorescence relative to
A549-Vector cells, as measured by flow cytometry. Values represent mean ± SD, nR 3 independent experiments.
(F) A549-Vector and A549-IFITM3 were infected with lentivirus carrying VAPA-shRNA or SC-shRNA. After two days, cells then fixed, stained with Nile Red, and
subjected to flow cytometry analysis to measure intracellular cholesterol levels. See also Figure S3.
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IFITM3 Disrupts Cholesterol Homeostasisindicating the late endosomal localization of IFITM3 (Fig-
ure S2F). Additionally, we excluded other cellular compart-
ments, such as lipid droplet-containing vacuoles, as sites of
IFITM3 localization (Figure S3A). Confocal microscopy revealed
that endogenous VAPA partially colocalized with IFITM3 in the
enlarged CD63-containing endosomal compartments of A549-
IFITM3 cells (Figure S3B). These data demonstrate that IFITM3
is mainly present in late endosomal compartments, where it
partly colocalizes with VAPA. Although IFITM3 expression
dramatically affects the biogenesis of endosomal compart-
ments, leading to morphological changes of endosomal com-456 Cell Host & Microbe 13, 452–464, April 17, 2013 ª2013 Elsevierpartments (Feeley et al., 2011), its expression did not affect
endosomal CD63 and LAMP1 protein levels (Figure S3C).
Because IFITM proteins block the interaction between VAPA
and OSBP that mediates transfer of cholesterol between ER
and organelles (Ikonen, 2008), we determined the intracellular
cholesterol levels using the histochemical cholesterol markers,
filipin and Nile Red dyes. The CD63-positive endosomal com-
partments of A549-IFITM3 cells showed much higher choles-
terol levels than those of A549-vector cells (Figures 3A and
3B; Figures S3A, top panel, and S3D), and these cholesterol-
laden IFITM3-positive endosomal compartments were alsoInc.
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that has an important role in cholesterol homeostasis (Cheval-
lier et al., 2008; Kobayashi et al., 1999) (Figure 3C). Flow cytom-
etry and biochemical analyses showed that intracellular choles-
terol levels (total cholesterol and free cholesterol) were
considerably increased upon IFITM3 expression, whereas
they were apparently decreased by VAPA expression (Figures
3D and S3E). Furthermore, IFITM1 or IFITM2 expression led
to the increased endosomal cholesterol levels as seen with
IFITM3 expression (Figures S4A and S4B). Because choles-
terol-laden endosomal compartments suppress viral release
from late endosomes to the cytosol by inhibiting the fusion pro-
cess (Chevallier et al., 2008; Le Blanc et al., 2005), IFITM3-ex-
pressing cells were treated with the cholesterol-depleting agent
methyl-b-cyclodextrin (MbCD), followed by Nile Red dye stain-
ing to detect intracellular cholesterol levels or infection with
defective pseudoretroviruses to measure VSV entry. MbCD
treatment of IFITM3-expressing cells detectably reduced endo-
somal cholesterol levels and increased single-cycle viral entry
(Figures 3E and S4C). Furthermore, shRNA-mediated depletion
of VAPA expression also increased endosomal cholesterol
levels (Figures 3F, S4D, and S4E), which correlates with de-
creases in viral entry and replication (Figures 2D, 2E, and 2H).
These findings collectively indicate that IFITM3-mediated
disturbance of the VAPA-OSBP interaction results in choles-
terol accumulation in endosomal compartments, which ulti-
mately inhibits viral entry.
IFITM3-VAPA Interaction Is Required for the
Accumulation of Endosomal Cholesterol and the
Inhibition of Viral Entry
To demonstrate the specificity of IFITM3 action, the IFITM3DTM2
mutant that lacked its C-terminal TM2 region and was incapable
of interacting with VAPA (Figure S4F) was tested for its ability to
disturb cholesterol homeostasis and viral entry. Because of the
loss of VAPA interaction, expression of the IFITM3DTM2 mutant
neither led to the accumulation of endosomal cholesterol nor
blocked GFP-IAV and GFP-VSV replication (Figures S4G and
S4H). A549-IFITM3DTM2 cells were also incapable of inhibiting
viral entry when challenged in a single-cycle infection with defec-
tive pseudoretroviruses carrying VSV, IAV PR8 (H1N1), and
IAV Udorn (H3N1) glycoprotein (Figure S4I). However, the
IFITM3DTM2 mutant was apparently expressed at a lower level
compared to the IFITM3 wild-type (WT) and present throughout
the cytoplasm, unlike IFITM3 WT (Figures S4F and S4G). For
this reason, the TM2 region of IFITM3 was thus replaced with
the transmembrane region of CD4 or of transferrin receptor 1
(TR) to generate the IFITM3-CD4 and IFITM3-TR chimeras,
respectively (Figure 4A). Whereas bothmutant chimeras colocal-
ized with CD63 similar to IFITM3WT, neither the IFITM3-CD4 nor
the IFITM3-TR chimera was capable of binding VAPA (Figures 4B
and4C) and had any detectable effect on the interaction between
VAPA and OSBP (Figure S4J). Consequently, their expression
displayed little or no effect on the accumulation of endosomal
cholesterol (Figures 4B and S3E) and on the replication of GFP-
IVA and GFP-VSV (Figure 4D). Finally, the IFITM3-CD4 and
IFITM3-TR chimeras were also incapable of inhibiting viral entry
when challenged in a single-cycle infection with defective pseu-
doretroviruses carrying VSV, IAV PR8 (H1N1), and IVA UdornCell H(H3N1) glycoprotein (Figure 4E). These results collectively indi-
cate that the IFITM3 and VAPA interaction triggers the accumu-
lation of endosomal cholesterol and thereby inhibits viral entry.
IFITM3 Induces MVB Formation and VAPA Triggers
the Fusion between the Intraluminal Vesicles
and Limiting Membrane of MVBs
Confocal microscopy showed that IFITM3 expression led to a
pronounced enlargement of CD63-containing compartments,
which costained with the filipin cholesterol marker (Figure 5A,
upper panel). Consistently, transmission electron microscopy
(TEM) and immunogold electron microcopy (EM) also revealed
that IFITM3 robustly induced multivesicular body (MVB) forma-
tion and was primarily present in the abundant intraluminal ves-
icles, whereas a minor population of IFITM3 was also present on
the cell surface (Figures 5B and S5A). Strikingly, confocal micro-
scopy showed that VAPA expression altered these IFITM3-
induced enlarged MVBs to become ‘‘ring’’-shaped structures
that hardly costained with filipin (Figure 5A, lower panel). TEM
and immunogold EM also revealed that upon VAPA expression
in A549-IFITM3 cells, the intraluminal vesicles of MVBs were
pushed to the edges and apparently fused with the surrounding
limiting membrane (Figures 5C and S5B) and that levels of this
‘‘ring form’’ structure of the endosomal compartments of
A549-IFITM3-VAPA cells were markedly higher than those of
A549-IFITM3 cells (Figure 5D). Of note, immunogold EM also
showed that VAPA was present in the cytoplasmic ER and endo-
somal compartments of the IFITM3 and IFITM3-VAPA cell lines
(Figures S5C and S5D). A549-vector and A549-VAPA cells
showed normal structural morphology though A549-VAPA cells
exhibited swollen endoplasmic reticulum. There were no alter-
ations in MVB formation in both cell lines (Figures S5E and
S5F). These results demonstrate that IFITM3 expression robustly
induces MVB formation, whereas VAPA expression appears to
trigger the fusion between the intraluminal vesicles and limiting
membrane of MVBs.
IFITM3 Impedes Vesicle Membrane Fusion to Block
the Cytosolic Release of Virion Particles
It has been shown that during VSV entry, viral fusion occurs in the
abundant internal vesicles of MVBs first, followed by the back-
fusion of these internal vesicles with the limitingMVBmembrane,
ultimately leading to the cytoplasmic delivery of VSV nucleocap-
sids (Le Blanc et al., 2005; Uchil and Mothes, 2005). As shown in
Figure 2, IFITM3 inhibits the early stage of VSV entry, but this
inhibition was compromised by VAPA expression. Consistently,
TEM also revealed that VSV particles were extensively packed
within the MVBs of A549-IFITM3 cells (Figures 6A and Fig-
ure S6A). On the other hand, only limited numbers of VSV parti-
cles were observed in the MVBs of A549-IFITM3-VAPA cells,
where the intraluminal vesicles of MVBs were apparently fused
with the surrounding limiting membrane (Figures 6B and S6B).
To further delineate VSV entry, A549-IFITM3 and A549-IFITM3-
VAPA cells were immunolabeled with 15 nm nano-gold-conju-
gated anti-Myc antibody to detect Myc-tagged IFITM3 and
30 nm nano-gold-conjugated anti-VSV-G antibody to detect
the VSV glycoprotein. Immunogold EM revealed that the VSV-
G protein accumulated in the abundant intraluminal vesicles of
MVBs of A549-IFITM3 cells, where IFITM3 was also presentost & Microbe 13, 452–464, April 17, 2013 ª2013 Elsevier Inc. 457
Figure 4. IFITM3-VAPA Interaction Is Required to Restrict Viral Entry
(A) Schematic illustration of IFITM3 chimera carrying the CD4 transmembrane (IFITM-CD4) or transferrin receptor transmembrane (IFITM3-TR). WCLs were used
for IB with the indicated antibodies.
(B) A549-Vector, A549-IFITM3, A549-IFITM3-CD4, and A549-IFITM3-TR cells were fixed and stained with anti-Myc (IFITM3), anti-CD63, or Nile Red dye for
confocal microscopy. DAPI was used to stain the nucleus. Scale bar, 5 mm. The metric values (mean ± SD) represent the quantitative assessment of the
colocalization of CD63 (top panel) and Nile Red (bottom panel) with IFITM3 WT and chimeras (Pearson’s coefficient, mean ± SD, nR 20).
(C) Lysates of A549-Vector, A549-IFITM3, A549-IFITM3-CD4, and A549-IFITM3-TR cells were used for IP and IB. WCLs were used for IB analysis to show
expressions of VAPA, IFITMs, and tubulin.
(D) A549-Vector, A549-IFITM3, A549-IFITM3-CD4, and A549-IFITM3-TR cells were infected with GFP-VSV (top panel) or GFP-IAV PR8 (bottom panel). At 48 hr
postinfection, cells were photographed under immunofluorescence microscopy (magnification: 43).
(E) A549-Vector, A549-IFITM3, A549-IFITM3-CD4, and A549-IFITM3-TR cells were infectedwith defectiveMLV-EGFP pseudotypedwith the envelope proteins of
VSV, IAV H1N1 (PR8), or IAV H3N1 (Udorn). Viral entry is expressed as mean EGFP fluorescence relative to vector control cells, as measured by flow cytometry.
Values represent mean ± SD, nR 3 independent experiments. See also Figure S4.
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IFITM3 Disrupts Cholesterol Homeostasis(Figures 6A and S6C). In striking contrast, both the VSV glyco-
protein and IFITM3 were located at the surrounding limiting
membrane of MVBs in A549-IFITM3-VAPA cells (Figures 6B
and S6D). These results demonstrate that VSV particles accu-
mulate in the intraluminal vesicles of MVBs in IFITM3 expressing
cells, whereas they are redistributed near to the surround-
ing limiting membrane of MVB upon VAPA expression. This
suggests that IFITM3 compromises VAPA function to disturb en-
dosomal cholesterol levels, blocking fusion between the intralu-
minal vesicles and limiting membrane of MVBs and thereby
inhibiting viral release to the cytosol.458 Cell Host & Microbe 13, 452–464, April 17, 2013 ª2013 ElsevierDISCUSSION
IFITM proteins are a family of small ISGs that possess various
functions, including adhesion, antiproliferation, apoptosis,
development, bonemineralization, and tumor progression (Sieg-
rist et al., 2011; Zhang et al., 2012). Although IFITM proteins were
identified around two decades ago, their antiviral role was
discovered recently and has been suggested to be a potential
target for antiviral therapy against human pathogenic viruses,
including IAV, Ebola virus, dengue virus, West Nile virus, and
SARS coronavirus. Despite active investigations, a detailedInc.
Figure 5. Effects of IFITM3 and VAPA Expression on MVB Structures
(A) A549-IFITM3 and A549-IFITM3-VAPA cells were stained with filipin, anti-Myc (IFITM3), and anti-CD63 for confocal microscopy. The inserts at the right panels
show themagnified images of the ‘‘filled form’’ (top panel) or the ‘‘ring form’’ (bottom panel) of endosomal compartments. Scale bar, 10 mm. The numbers indicate
the Pearson’s correlation coefficient for colocalization of filipin and IFITM3 within endosomal compartments (mean ± SD, nR 100 endosomal compartments).
(B and C) A549-IFITM3 and A549-IFITM3-VAPA cells were subjected to TEM and immunogold EM (anti-Myc and 15 nm gold particle-conjugated secondary
antibody) as described in the Experimental Procedures. Magnified images of the inserts are shown in the bottom of the panel. Scale bar, 0.2 mm.
(D) Bar graphs represent the percentages of the ‘‘filled form’’ or the ‘‘ring form’’ structure of endosomal compartments within A549-IFITM3 and A549-IFITM3-
VAPA cells from TEM images (nR 100 endosomal compartments). See also Figure S5.
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IFITM3 Disrupts Cholesterol HomeostasisIFITM-mediated antiviral mechanism has been elusive. In this
study, we report that IFITM1, IFITM2, and IFITM3 interact with
VAPA, and this interaction antagonizes VAPA-OSBP function,
disturbing intracellular cholesterol homeostasis, resulting in
cholesterol-ladenMVBs and late endosomes and thereby block-
ing viral release to the cytosol (Figure 7).
VAPA and VAPB are type II membrane proteins that are
conserved from yeast to human and generally localize in the
ER and other subcellular organelles (Lev et al., 2008). VAPA is
involved in vesicle transport and membrane fusion though the
precise details of its functions are unclear. It also plays an impor-
tant role in cholesterol homeostasis through its interaction with
cytosolic cholesterol sensor, OSBP (Holthuis and Levine, 2005;
Maxfield and Tabas, 2005; Raychaudhuri and Prinz, 2010).
VAPA is composed of three domains: a major sperm protein
(MSP) domain, a coiled-coil domain (CCD), and a transmem-
brane (TM) domain. Based on a previous report (Wyles et al.,Cell H2002) and our study, the N-terminal MSP domain of VAPA suffi-
ciently binds to OSBP, whereas the central CCD and C-terminal
TM of VAPA are responsible for IFITM interaction. These suggest
that VAPA may independently interact with OSBP and IFITMs,
yet we found that IFITM3 interaction effectively suppressed the
interaction between VAPA and OSBP. On the other hand, neither
OSBP expression nor OSBP depletion had effect on the IFITM3-
VAPA interaction and IFITM3-mediated antiviral activity. Howev-
er, these resultsmay not be conclusive because there are at least
12 different isoforms of OSBP (Raychaudhuri and Prinz, 2010).
Nevertheless, our result suggests that IFITM3 interaction may
considerably change VAPA structure or localization to disrupt
OSBP binding and thus disturb intracellular cholesterol homeo-
stasis. Two reports have recently shown that S-palmitoylation
of the membrane-proximal cysteine residue of IFITM3 positively
impacts its antiviral activity (Yount et al., 2010), whereas the
posttranslational K48 and K63 ubiquitination of IFITM3 haveost & Microbe 13, 452–464, April 17, 2013 ª2013 Elsevier Inc. 459
Figure 6. TEM and Immunogold EM of VSV-Infected A549-IFITM3 and A549-IFITM3-VAPA Cells
(A and B) A549-IFITM3 and A549-IFITM3-VAPAweremock infected (left panel) or with high titers of VSV for 1 hr (rest of panels). Then cells were washed to remove
unbound viruses and subjected to TEM (scale bar, 0.1mm)and immunogold EM (scale bar, 0.2mm) asdescribed in theExperimental Procedures. Dual immunogold
labeling was performed with anti-Myc antibody and 15 nm gold particle-conjugated secondary antibody (IFITM3, filled triangle) and anti-VSVgp antibody and
30 nm gold particle-conjugated secondary antibody (VSVgp, open arrow). The areas of particular MVBs are marked by dashed lines. See also Figure S6.
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IFITM3 Disrupts Cholesterol Homeostasisnegative effect on its antiviral activity (Yount et al., 2012).
Furthermore, based on posttranslational modification studies,
a new dual-pass transmembrane topology of IFITM, in which
the N terminus and C terminus of IFITM are concurrently cyto-
plasmic (Yount et al., 2012), has been introduced. Jia and col-
leagues (Jia et al., 2012) have also shown that the first 21 amino
acids of the IFITM3 N terminus are important for IFITM3 reloca-
tion to the endosomal compartment and lacking of this region
impairs IFITM3 function; specifically, the tyrosine residue at the
PPNY motif (amino acids 17–20) is critical for IFITM3 function.
Although we and others (Diamond and Farzan, 2013) showed
that the IFITM termini existed extracellularly at the plasma mem-
brane, this new anticipated IFITM topology would not be incon-
sistent with our proposed model (Figure 7) because the TM2 of
IFITM3 interacts with VAPA to control intracellular cholesterol
levels. It has been shown that the Norwalk virus nonstructural
protein p48 interacts with VAPA, and this interaction affects
intracellular trafficking pathways (Ettayebi and Hardy, 2003). In
addition, hepatitis C virus (HCV) has been shown to target both
VAPs and OSBP to regulate viral replication. Specifically, the
NS5A and NS5B proteins of HCV interact with VAPA and VAPB
isoforms, and these interactions positively affect HCV replication
(Gao et al., 2004; Hamamoto et al., 2005). Additionally, the N-ter-
minal domain of the HCV NS5A protein interacts with OSBP,
which is important for HCV particle release (Amako et al.,
2009). However, none of these studies have detailed how these
interactions specifically affect viral replication and maturation.
Because cholesterol is an essential molecule for the life cycle
of HCV, targeting VAPA andOSBPmay not only play a significant460 Cell Host & Microbe 13, 452–464, April 17, 2013 ª2013 Elsevierrole in HCV replication and pathogenesis butmay also lead to the
evasion of IFITM-mediated antiviral activity. These studies are
currently under active investigation.
Accumulation of cholesterol within late endosomal compart-
ments has been shown to impair their function, significantly im-
pairing the infection of certain viruses that enter the cell through
endocytosis, such as IAV, VSV, and dengue virus (Lakadamyali
et al., 2004; Pattanakitsakul et al., 2010). We showed that IFITM3
expression induces substantial accumulation of cholesterol
within MVBs and late endosomal compartments in a VAPA-bind-
ing-dependent manner. We also reproducibly observed the tran-
sient increase of cholesterol accumulation in endosomes as well
as the pronounced enlargement of cholesterol-enriched late
endosomal compartments upon IFN-b treatment (data not
shown), suggesting that our observations of IFITM3 expression
are physiologically relevant. However, levels of the intracellular
cholesterol accumulation induced by IFN-b treatment were
weaker than those induced by IFITM3 overexpression, which
may be because IFN-b treatment affects expressions of over
300 genes, including the genes for cholesterol synthesis and
cholesterol efflux. Furthermore, a recent paper (Roth and Whit-
taker, 2011) has reported that the endosome-specific LBPA
selectively increases the rate of VSV G-mediated membrane
fusion, but not the rate of IAV HA-mediated membrane fusion.
On the other hand, the HA-mediated membrane fusion is depen-
dent on the dynamic molecular shape of lipids because it is
inhibited by the inverted cone-shaped lipid lysophosphatidyl-
choline but promoted by oleic acid (Chernomordik et al., 1997).
In contrast, we show that the increase of endosomal cholesterolInc.
Figure 7. Schematic Model of IFITM3-Mediated Inhibition of Viral Entry
Schematic model represents viral infection in the absence (left panel) or presence (right panel) of IFITM induction. Virions (depicted as stars) enter the cell by
endocytosis, are subsequently transferred to early endosome (EE), and are finally transferred to late endosome/multivesicular body (LE/MVB). In the absence of
IFITM induction under normal cholesterol (depicted as its chemical shape) homeostasis conditions, the intraluminal virion-cargo-containing vesicles or virion
particles finally fusewith the limitingmembrane to release viral genome or nucleocapsid to the cytosol. In the presence of IFITM induction, IFITM-VAPA interaction
disturbs intracellular cholesterol homeostasis, leading to the accumulation of cholesterol in LE/MVB. This consequently blocks the fusion of the intraluminal
virion-cargo-containing vesicles or virion particles with the limiting membrane of LE/MVB compartments.
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IFITM3 Disrupts Cholesterol Homeostasisinduced by IFITMs leads to the efficient inhibition of VSV and
IAV entry, suggesting that each lipid moiety may have different
selectivity and activity to regulate fusion events upon viral entry.
When the IFITM3 TM2 region was deleted or replaced with the
TM regions of other proteins, VAPA interaction was completely
lost, and accordingly, there was no cholesterol accumulation
(Figure 4; Figures S4F–S4I). Interestingly, IFITM3-expressing
cells show similar phenotypes to cells derived from NPC1 dis-
ease, an autosomal disorder with massive accumulation of
cholesterol in late endosomal compartments (Peake and Vance,
2010; Subramanian and Balch, 2008). When NPC1 cells were
challenged with various viruses, they also showed defect in viral
infection, particularly at the entry step (Gruenberg, 2009;
Kobayashi et al., 1999; LeBlanc et al., 2005). Furthermore, recent
studies have identified that membrane fusion mediated by filovi-
rus glycoproteins and viral escape from the vesicular compart-
ment require the NPC1 protein. Specifically, NPC1 directly binds
the viral glycoprotein (GP), which ultimately facilitatesmembrane
fusion to induce viral release to the cytosol (Carette et al., 2011;
Coˆte´ et al., 2011). Several pieces of evidence also indicate that
members of the Rab GTPase family, such as Rab7 and Rab9,
may impair cholesterol accumulation, and thus expression of
these Rab GTPases complemented the defects seen in NPC1
cells, decreasing endosomal cholesterol levels and subse-
quently allowing viral infection (Ganley and Pfeffer, 2006; Leb-
rand et al., 2002; Narita et al., 2005; Zhang et al., 2009). However,
expression of the Rab7, NPC1, or NPC2 gene in A549-IFITM3
cells neither decreased endosomal cholesterol levels norCell Hincreased VSV and IAV infection (J.U.J. and S.A.-B.-O., unpub-
lished data). In contrast, VAPA expression reduced endosomal
cholesterol levels and ultimately enhanced VSV and IAV infec-
tion. Furthermore, the accumulation of cholesterol in late endo-
some of NPC cells and U18666A-treated cells led to a 2- to
3-fold increase in the size of the compartments. Most impor-
tantly, the properties and dynamics of the intraluminal vesicles
of late endosomes showed reduced back fusion with the limiting
membrane and blocked VSV release to the cytosol (Sobo et al.,
2007). These suggest that the pathological accumulation of
cholesterol induced by IFITM3 dramatically perturbs the fusion
between the intraluminal vesicles or virion-containing compart-
ments and the limiting membrane of MVBs, ultimately blocking
viral release to the cytosol (Figure 7). These also indicate that
IFITM3-expressing cells phenocopy NPC1 cells but utilize a
different mechanism to induce the accumulation of endosomal
cholesterol and thereby block viral entry. Of note, IAV and VSV
use the classical endocytosis pathway that is dependent of cav-
eolin- and clathrin-coated pits. After endocytosis, the virions
ultimately travel to lysosomal compartments for cytosolic
release, which is targeted by IFITM3. However, MLV is generally
released to cytosol right after endocytosis without reaching lyso-
somal compartments. Specifically, upon fusion event between
the MLV particles and host plasma membranes, virion cores
are immediately delivered to the cytoplasm (Diamond and Far-
zan, 2013). Arenaviruses, including LCMV, LASA, and MACH,
are internalized to cell via an unusual pathway of endocytosis
that is independent of clathrin and caveolin (Kunz, 2009; Rojekost & Microbe 13, 452–464, April 17, 2013 ª2013 Elsevier Inc. 461
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IFITM3 Disrupts Cholesterol Homeostasisand Kunz, 2008). Thus, the IFITM3 action at the lysosomal com-
partments appears to be a key factor for its specific effect on IAV
and VSV entry. In summary, our study shows an antiviral strategy
in which IFITM proteins, as specific infection-induced host
defense effectors, target VAPA to deregulate the integrity of
cholesterol homeostasis necessary for the ordered release of
infectious virion particles. These observations also offer IFITMs
as targets for therapeutic avenues to combat viral infections.
EXPERIMENTAL PROCEDURES
Yeast Two-Hybrid Screening
IFITM3 full-length cDNA (NM_021034) was purchased from Open Biosystems
(Lafayette, CO, USA) and cloned into the BamHI-EcoRI sites of the
pGBKT7 vector (Clontech Laboratories, Mountain View, CA, USA) as bait.
Saccharomyces cerevisiae, strain AH109, was transformed with the
pGBKT7-IFITM3 vector. AH109 yeast expressing IFITM3 was subjected to
Y2H library-scale transformation. A human leukocyte matchmaker cDNA li-
brary fused to a GAL4-activating domain in the pACT2 vector (Clontech Lab-
oratories) was utilized for Y2H library-scale screening in accordance with
Matchmaker Two-Hybrid System 3 instructions (Clontech Laboratories).
Transfection of IFITM3, VAPA, and OSBP
VAPA cDNAwas purchased (OpenBiosystems) andPCRcloned into theEcoRI-
BamHI site of the lentivector pCDH-MCS-EF1-Neo mammalian expression
system (System Biosciences, Mountain View, CA, USA). Puromycin-resistant
A549-IFITM3 and A549-vector cells were infected by lentivirus pseudotyped
with the Machupo virus glycoprotein (MACHgp) carrying VAPA or VAPA-FLAG.
MACHgp was used instead of vesicular stomatitis virus glycoprotein (VSVgp)
because IFITM3 robustly restricts VSVgp-mediated entry (Brass et al., 2009).
Cell Culture, Immunoblotting, Immunoprecipitation, and GST
Pull-Down
A549 cells were maintained in RPMI-1640 medium supplemented with 10%
fetal bovine serum ( Gibco Life Technologies, Grand Island, NY, USA), nones-
sential amino acids (Gibco), and appropriate antibiotics. Puromycin (Invitro-
gen, Carlsbad, CA, USA) and G418 antibiotics were used to generate cell lines.
Western blot (WB) and coimmunoprecipitation (coIP) were performed in accor-
dance with standard protocols.
VAPA shRNA Silencing
To deplete VAPA gene expression, several shRNAs targeting the VAPA gene
were designed and cloned into the AgeI-EcoRI site of the pLKO.1-TRC-puro
lentivector (Addgene, Cambridge, MA, USA).
Influenza Virus and VSV Infection
Influenza A virus PR8 (A/PR8/H1N1) and influenza virus GFP-PR8 strains
(Manicassamy et al., 2010) were obtained from Dr. Adolfo Garcı´a-Sastre
(Mount Sinai School of Medicine), and VSV-GFP and VSV-WT viruses were
kindly provided by Dr. Sean Whelan (Harvard Medical University). Cells were
infected with influenza and VSV viruses, and viral infection was determined
by standard plaque assay.
Defective MLV-EGFP Pseudotyped Virus Production and Entry
Assay
To generate defectiveMLV-EGFP pseudotyped virus coatedwith different viral
envelopes, 293T cells were cotransfected with pQCXIP-EGFP-retrovirus-
based plasmid (Clontech), together with MLV gag/pol expression vector and
a viral envelopeexpressionplasmidaspreviously described (Brass et al., 2009).
Confocal, Immunofluorescence Microscopy, Colocalization
Analysis, and Cholesterol Quantification
A549 cells were fixed in PBS containing 4% formaldehyde, permeablized with
0.5% Triton X-100, blocked with 1% BSA, and then stained with indicated
antibodies for confocal microscopy (Nikon Eclipse Ti). The Pearson’s correla-
tion coefficients of the different fluorescent signals were determined for coloc-462 Cell Host & Microbe 13, 452–464, April 17, 2013 ª2013 Elsevieralization analysis. Total-, free-, and esterified-cholesterols were measured
using the Cholesterol Quantification Kit (Sigma-Aldrich, St. Louis).
Electron Microscopy
Standard protocols were used for sample preparation, transmission electron
microscopy (TEM), and immunoelectron microscopy. Electron microscopy
experiments were carried out at the USC/Norris Cell & Tissue Imaging Core
within the Vision Research Center.
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